skip to Main Content

Stereotactic Body Radiotherapy Promising for Pancreatic Cancer

Stereotactic Body Radiotherapy Promising for Pancreatic Cancer
The addition of stereotactic body radiotherapy to chemotherapy extended OS among patients with unresectable pancreatic cancer, according to data from a retrospective analysis

Five-year survival rates for patients with pancreatic cancer remain low, at less than 8%. Complete surgical resection extends survival. However, between 80% and 85% of patients present with unresectable disease. Read more . . .


Back To Top